Indivior (INDV) Financial and Legal Issues Case
$INDV stockholders filed a claim against Indivior for overstating its ability to predict new laws' impact, revenue, and 2024 targets.
After the financial results on July 9, 2024, $INDV dropped by 33.57%.
Indivior investors can join this case to be notified about potential recovery.
Case Details:
Between February 22, 2024, and July 8, 2024, Indivior told investors it expected to generate higher revenue in 2024.
The company projected earnings of $1.24-$1.33B, mostly from selling its main product, SUBLOCADE, and new products like OPVEE and PERSERIS.
On April 25, 2024, Indivior told investors that challenges like fewer Medicaid patients and competition were temporary and wouldn’t affect revenue. However, they underestimated the impact of new laws on their products.
On July 9, 2024, Indivior cut its revenue forecast, admitting new laws had a bigger impact than expected. They also decided to stop selling PERSERIS due to increased competition.
On this news, $INDV dropped by 33.57% on the same day.
Based on these events, $INDV stockholders filed a claim against Indivior and its leaders, accusing them of the following:
Indivior overstated its ability to predict the impact of new laws on its products.
The company overestimated revenue for SUBLOCADE, PERSERIS, and OPVEE.
It ignored risks from new legislation, making it unlikely to meet 2024 revenue targets and risking the end of PERSERIS sales.
Considering all the representations, investors suspect that Indivior overstated its ability to predict new laws' impact, revenue, and 2024 targets.